United Therapeutics Corporation logo UTHR - United Therapeutics Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 17
HOLD 12
SELL 1
STRONG
SELL 0
| PRICE TARGET: $643.75 DETAILS
HIGH: $735.00
LOW: $515.00
MEDIAN: $662.50
CONSENSUS: $643.75
UPSIDE: 32.02%

Stock News

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication. “.

Sep 02, 2026 03:00 AM • businesswire.com
Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR

Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR

Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDAQ: UTHR) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,200 shares of the biotechnology company's stock, valued at approximately $3,359,000. A number of other institutional investors and hedge

Aug 31, 2026 01:42 AM • defenseworld.net
Freestone Grove Partners LP Acquires New Stake in United Therapeutics Corporation $UTHR

Freestone Grove Partners LP Acquires New Stake in United Therapeutics Corporation $UTHR

Freestone Grove Partners LP bought a new position in United Therapeutics Corporation (NASDAQ: UTHR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,207 shares of the biotechnology company's stock, valued at approximately $654,000. A number of other large investors have also

Aug 31, 2026 01:09 AM • defenseworld.net
Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR

Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR

Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ: UTHR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 15,582 shares of the biotechnology company's stock, valued at approximately $8,443,000. Other institutional investors and hedge funds also recently

Aug 31, 2026 01:09 AM • defenseworld.net
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona. The presentations include late-breaking a.

Aug 28, 2026 03:00 AM • businesswire.com
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. “Ralinepag has the potential to make an important difference.

Aug 24, 2026 03:00 AM • businesswire.com
Allworth Financial LP Invests $632,000 in United Therapeutics Corporation $UTHR

Allworth Financial LP Invests $632,000 in United Therapeutics Corporation $UTHR

Allworth Financial LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,167 shares of the biotechnology company's stock, valued at approximately $632,000. Other institutional investors also recently

Aug 23, 2026 11:55 PM • defenseworld.net
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients. “The rapid pace of enrollment underscores both the significant unmet need for new treatment options in PPF and the strong interest in nebulized Tyvas.

Aug 17, 2026 03:00 AM • businesswire.com

Price Targets